Objective:To investigate the efficacy of nucleoside antiviral drug entecavir combined with bifidobacterium triple live capsule in the treatment of patients with hepatitis B cirrhosis. Methods:132 patients with hepatitis B cirrhosis admitted to our hospital from May2015 to April 2017 were randomly divided into two groups. The combination group was treated with entecavir and microecological preparations. The liver function indexes were compared between the two groups before and after treatment. Fibrosis markers and immune function related indicato rs (P ＜0.05) . There was no significant difference between the two groups before treatment (P＞0.05) . After treatment, both decreased, the study group was significantly better than the control group (P＜0.05) . There was no significant difference in the liver fibrosis indexes between the two groups before treatment (P＞0.05) . After treatment, both decreased, the study group was significantly better than the control group (P＜0.05) . After treatment, the patients were significantly improved, and the study group was significantly better than the control group (P＜0.05) . Conclusion:Hepatitis B cirrhosis patients treated with entecavir and Bifidobacterium triple live capsules are beneficial to improve the therapeutic effect and improve liver function, liver fibrosis and immune function.%目的:探讨核苷类抗病毒药恩替卡韦联合双歧杆菌三联活菌胶囊治疗乙肝肝硬化的疗效.方法:选取2015年5月～2017年4月我院收治的乙肝硬化患者132例, 按随机数表法分为两组, 对照组应用恩替卡韦治疗, 研究组联合应用恩替卡韦以及微生态制剂治疗, 对比两组治疗前后肝功能指标、肝纤维化指标以及免疫功能指标.结果:研究组治疗有效率显著高于对照组 (P＜0.05) ;治疗前两组肝功能指标无明显区别 (P＞0.05) , 治疗后均得到下降, 研究组显著优于对照组 (P＜0.05) ;治疗前两组肝纤维化指标无明显区别 (P＞0.05) , 治疗后均得到下降, 研究组显著优于对照组 (P＜0.05) ;治疗前两组免疫功能指标无明显区别 (P＞0.05) , 治疗后均得到下降, 研究组显著优于对照组 (P＜0.05) .结论:乙肝肝硬化联合应用恩替卡韦以及双歧杆菌三联活菌胶囊进行治疗, 有利于提高治疗效果, 改善肝功能、肝纤维化及免疫功能指标.
展开▼
